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Abstract This research illustrates regional differences in the business development 
practices of pharmaceutical wholesalers among Japan, the US, and Europe. Specifi-
cally, it examines factors that result from regional differences in power relationships 
among healthcare providers. Market characteristics of each country affect delivery 
frequency, trade volume per order, and the size and the density of wholesalers’ distribu-
tion centers. As it is becoming increasingly difficult for the pharmaceutical industry in 
the US and Europe to profit from wholesaling, these businesses are diversifying into 
either pharmacy operations or manufacturing. These structural changes have become 
an important factor in determining regional differences in wholesalers’ business models 
and business development. Regional differences in pharmaceutical wholesaling result 
from wholesalers’ corporate strategies corresponding to each country’s market charac-
teristics. Wholesalers’ expected function differs from country to country. As a result, 
there are many differences in their relative risk. American and European wholesalers 
carry less risk in debt collecting than do manufacturers or users (purchasers). In con-
trast, in Japan, risk is higher among pharmaceutical wholesalers compared to manufac-
turers and medical institutions or pharmacies.
Key words : pharmaceutical distribution, pharmaceutical wholesaler, Japan, the US, 
Europe
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1. Introduction
Pharmaceutical manufacturers develop their products for the global market. In contrast, 
pharmaceutical wholesalers must adapt to the local market characteristics of their customers. 
This is because pharmaceutical market characteristics are affected by each country’s healthcare 
system, which includes its drug pricing. These market characteristics define the power rela-
tionships among healthcare providers in terms of price determination. Pharmaceutical prices 
in the US are based on the free market, while prices in most European countries and in Japan 
are based on pharmaceutical pricing policies. European wholesalers are at the mercy of gov-
ernment-imposed margins and/or price cuts. Japanese wholesalers, however, must negotiate 
prices with both manufacturers and customers. This has an impact on the business model of 
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pharmaceutical wholesalers, which are located at the intermediate step of the distribution pro-
cess.
In Japan, many geographers have focused on the distributors’ function in the adjustment of 
the flow of both physical goods and information. These geographers have demonstrated ways 
to exploit information and communication technology (ICT) for both its competitive advantage 
and the spatial impact it brings (Aoyama, 2001 ; Arai, 1989 ; Iida, 1993 ; Kawabata, 1990, 
1995 ; Tsuchiya, 1998 ; Nakamura, 2003, 2005 ; Hashimoto, 2001, 2002, 2003a, 2003b). 
Hashimoto (2000) examined the process of formation in the vertical collaborative relationship. 
He related these distribution channels to information systems, and pointed out that progress in 
ICT will result in a wholesale industry that will decrease in size and whose market will become 
monopolized by a few leading companies. This will be especially so for Japan’s pharmaceutical 
distribution system, wherein pharmaceutical wholesalers have reorganized the existing distri-
bution system through ICT, in the face of the National Health Insurance (NHI)’s price revision 
and the deregulation of their distribution. Kawabata (1990, 1995) and Nakamura (2003) exam-
ined the ways in which pharmaceutical wholesalers have adapted to this ICT progress ; they 
analyzed the consequent functional division and locational change among such pharmaceutical 
establishments as branch offices and distribution centers.
Kawabata (1990, 1995) pointed out that spatial proximity based on face-to-face contact has 
ceased to be an absolute requirement for sharing information. This is due to progress in the 
information and communications network, which have led to a decrease in the number of branch 
offices and distribution centers and the spatial separation of the industry’s operational and dis-
tribution functions. Nakamura (2003) illustrated that, for locational change of Japanese phar-
maceutical wholesalers caused by improvements in the information network, the separation of 
trade information flow and goods delivery has shifted the latter function from the core of urban 
centers to their suburbs. Moreover, the intra-firm separation of the over-the-counter (OTC) 
drug and prescription drug segment has led to a locational reorganization of branch offices. 
There are two reasons for this : First, the online ordering system, in the OTC segment where 
price has been deregulated, has permitted delivery centers and branch offices to become cen-
tralized, usually in prefecture centers. Second, the prescription drugs segment requires the 
advanced communicative functions of product information and quick delivery. In this way, the 
distribution system has been reconstructed to suit each product.
Spatial formation of pharmaceutical wholesalers varies by region, among Japan, the US, and 
Europe. These market characteristics are largely shaped by the institutional, social, and cul-
tural aspects of specific regions, which account for regional differences in the development of 
the wholesale pharmaceutical business. Nonetheless, these regional differences and the fac-
tors that influence them are not completely understood from an institutional context. This 
research illustrates regional differences in the business development of pharmaceutical whole-
salers among Japan, the US, and Europe. It also examines the factors that lead to regional dif-
ferences in power relationships among healthcare providers.
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2. Healthcare’s institutional environment and pharmaceutical distribution
When considering a health care system from the point of view of financial resources (Table 
1), we might define three types in developed countries. The first type is established within 
the government’s general budget. A noteworthy example is the UK’s National Health Service 
(NHS). The second is the social insurance system, adopted by countries such as Germany, 
France, and Japan. The third is the system provided mainly by private health insurance 
adopted by the US. In addition, the US healthcare system includes Medicare and Medicaid. 
On the one hand, Medicare provides health insurance coverage to people who are aged 65 and 
over, or who meet other special criteria. On the other, Medicaid provides coverage to eligible 
individuals and families with low incomes and few resources.
As the drug pricing system varies among regions, the competitive position among whole-
salers also has differing regional characteristics. In the UK, the NHS presents the list price, 
which is determined through negotiations between it and the pharmaceutical manufacturers, 
and sets the wholesale margin at 12.5%. Also, pharmacies are offered an approximate 10% 
discount, according to their purchase volume. In Germany and France, the government sets 
the mark-up and offers pharmacies a several percentage discount. In most European coun-
tries, the drug pricing scheme is one wherein the official margin is determined according to the 
drug price, and pharmaceutical wholesalers compete with each other.
In contrast, in the US, drug prices are set based on market principles through negotiations 
between pharmaceutical manufacturers and private health insurance companies. Since the 
1990s, on the contrary, pharmacy benefit managers (PBMs) emerged as drug benefit contrac-
tors and price negotiations are becoming increasingly severe for the manufacturers. The US 
pharmaceutical wholesalers get paid for providing manufacturers with their inventory or cus-
tomer information on a fee-for-service basis. Also during this period, the US wholesalers’ 
distribution centers’ gross margins rapidly decreased from 7% to around 4%, but over the past 
ten years the ratio has remained roughly flat. In 2008, however, the gross margin decreased to 
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3.1%.
Figure 1 shows pharmaceutical market size and market share for each region. The size of 
the North American pharmaceutical market is US$346 billion. In 2011, the US market share 
reached 40%, but recently, the annual market growth dramatically decreased. Europe is the 
second largest pharmaceutical market. The total market size of France, Germany and the UK 
combined accounts for about half the total European market. In the early 1990s, the Japanese 
market occupied a 30% share of the world market. The current Japanese market share, how-
ever, is approximately 11%.
In Japan, the government sets the NHI drug price, but since World War II, prescription 
drugs have been distributed based on market principles. Within this structure, price negotia-
tions take place among pharmaceutical manufacturers, drug wholesalers and such suppliers as 
medical institutions and pharmacies under the auspices of the NHI drug price scheme. In the 
1990s, after supposed standard prices were reduced and the pricing system was improved to 
include a new invoice pricing system, medical institutions could no longer depend on drug price 
margins. Since the late 1990s, the separation of the dispensary and prescription functions 
placed pharmacies together with existing medical institutions as customers of drug wholesal-
ers. In consideration of the dispersion of their customer base, these changes required that 
wholesalers control their prices, increase their ability to negotiate prices with customers, and 
deliver pharmaceuticals more efficiently. All these environmental changes brought about the 
need to invest in ICT and to expand in scale ; accordingly, since the 1990s, Japanese pharma-
ceutical wholesalers experienced repeated mergers and selective reorganization.
The ratio of wholesalers in the overall pharmaceutical supply industry also varies by region 
Figure 1 Market size (in constant US$B) and market share
  Source : GSK Annual Report, 2009, IMS Health Market Prognosis, May 2012.
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(Figure 2). In Europe, it accounts for 50 to 60%, and this relatively small ratio comes from the 
fact that specialty drugs for hospitals are delivered directly through pre-wholesalers and not 
through wholesalers. In the 1970s, in the US, wholesalers accounted for 50% of the overall 
pharmaceutical supply industry. Since then, the ratio has risen to as high as the 80% it is at 
present. The remaining 20% is accounts for direct delivery from pharmaceutical manufactur-
ers through mail order or through drugstore chains. As for Japan, with the exception of some 
generics, most pharmaceutical drugs are delivered by wholesalers.
In Europe, more than 90% of sales through wholesalers are delivered directly to pharma-
cies. Here, there is an apparent differentiation in the distribution channel, as manufacturers 
deliver pharmaceuticals for pharmacies and hospitals directly through wholesalers. In the US, 
wholesalers deliver to various customers such as pharmacies, hospitals, and HMOs. Their 
main customers are pharmacy chains. Wholesalers deliver 25% of their products to pharmacy 
chain warehouses and 18% to pharmacy chain stores. Deliveries to warehouses and mail order 
firms are a growing share of wholesalers’ sales. In these deliveries, the product can be deliv-
ered in bulk so that delivery is more efficient, although gross margins are reduced. In 2009, 
for Japanese wholesalers, as the separation of the dispensary and prescription functions steadily 
progressed, the share of wholesalers’ deliveries to pharmacies accounted for 50% and the 
remaining 50% went to medical institutions. This constituted a change from the previous five 
years, where 40% of deliveries went to pharmacies and 60% to medical institutions.
Figure 2 Distribution channels of pharmaceuticals
  Source : HDMA Factbook, Data of IMS, Cre-con report, Data of MHLW
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3. The pharmaceutical wholesaler’s business development 
3.1 Key differences among pharmaceutical wholesalers’ business operations
This section begins with an overview of the financial data for each region’s wholesalers 
(Table 2). In each pharmaceutical market, the top three wholesalers own 50% of the total 
European market share, 96% of the US market share, and 74% of Japanese market share 
respectively. The consolidated operating expense ratios and operating profit margins are high 
in Europe and low in the US. Japan occupies an intermediate position between Europe and the 
US. For each wholesaler, however, the business content segment differs, resulting in varying 
operating expense ratios and profit margins.
Table 2 shows that, for Japan’s wholesalers on average, the gross profit margin, the whole-
salers’ core competence measure, is as high as 6%. But for Celesio, one of Europe’s main 
pharmaceutical wholesalers, it is as low as 6.3%, and for US wholesalers on average, it is about 
4%. The operating expense ratio is also as high as approximately 6% for Japan’s wholesalers, 
but is as low as 4% for Celesio, and approximately 2% for McKesson. These numbers reflect 
differences in content and function of the pharmaceutical wholesaling business.
Table 2 Operational figures for European, US, and Japanese wholesalers in fiscal 2011
Europe US Japan








Medipal Alfresa Suzuken Toho
Total
Sales ($ mil) 30,702 28,881 37,111 122,734 107,552 79,490 33,215 28,179 22,463 13,383
Gross profit margin 11.9% 9.2% 20.9% 5.4% 4.2% 3.4% 7.0% 6.2% 9.1% 8.8%
Operating expense ratio 9.7% 6.8% 15.7% 3.5% 2.5% 1.8% 6.2% 5.8% 8.7% 7.5%
Operating profit margin 2.2% 2.5% 5.2% 1.8% 1.7% 1.6% 0.8% 0.4% 0.4% 1.3%
Whole-
saling
Sales ($ mil) 25,092 NA 27,142 119,424 97,925 78,349 32,729 27,971 21,386 12,891
Gross profit margin 6.3% NA NA 4.2% NA NA 6.9% 5.8% 6.3% 6.8%
Operating expense ratio 4.1% NA NA 2.4% NA NA 6.1% 5.5% 6.5% 6.0%
Operating profit margin 2.3% NA 2.5% 1.9% 1.6% 1.6% 0.8% 0.4% −0.2% 0.9%
Retailing
Sales ($ mil) 4,760 NA 12,373 0*3 0*4 0 0 0 926 914
Gross profit margin 32.9% NA NA 0.0% 0.0% 0.0% 0.0% 0.0% 34.6% NA
Operating expense ratio 27.8% NA NA 0.0% 0.0% 0.0% 0.0% 0.0% 28.8% NA
Operating profit margin 5.1% NA 10.6% 0.0% 0.0% 0.0% 0.0% 0.0% 5.7% 6.1%
Others
Sales ($ mil) 511 NA 411 3,310 9,642 1,325 515 323 1,074 19
Gross profit margin NA NA NA 45.6% NA NA NA 34.3% 36.5% NA
Operating expense ratio NA NA NA 34.8% NA NA NA 32.3% 30.2% NA
Operating profit margin NA NA −12.5% 11.0% 3.4% 5.4% NA 2.0% 6.3% 29.8%
Note1 : Exchange rate is 0.62 pounds, 0.75 euros and 82.8 yen to the dollar, respectively.
Note2 : The franchise pharmacy McKesson Health Mart is included in the wholesaling segment.
Note3 :  The franchise pharmacy Cardinal Health, Medicine Shoppe International, is included in the whole-
saling segment.
Source : Annual report of each pharmaceutical wholesaler
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The differences in wholesaling business functions by region are summarized as follows. 
European wholesalers distribute pharmaceuticals several times a day through the 20 to 30 
medium-sized distribution centers they have established in each county (Figure 3). The US 
wholesalers perform an efficient, once-a-day pharmaceutical distribution to the approximately 
30 large distribution centers they maintain across the country. They deliver in bulk and give 
large discounts to the distribution centers of drugstore chains. This leads to a reduction in 
delivery frequency and the density of wholesalers’ distribution centers, but an increase in both 
trade volume per order and size of distribution center.
Japanese wholesalers distribute pharmaceuticals through their approximately 20 centers to 
their about 200 branch offices throughout the country (e.g., 17 distribution centers and 238 
Figure 3 Location of distribution centers
  Source : website of each pharmaceutical wholesaler
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branch offices of Suzuken). Japanese wholesalers must deliver pharmaceuticals to 220,000 
customers, including pharmacies and medical institutions. Going through multiple branch 
offices allows wholesalers to maintain a balance between inventory reduction and the shorten-
ing of lead time due to the increasing number of generics and shipping points (Nakamura, 2013). 
Each depot covers a small delivery area with small trade volume per order and a high delivery 
frequency. This requires that the structure of Japanese wholesalers’ distribution space is mul-
tilayered. Japanese and European wholesalers share a similar feature, but the former encom-
passes factors that increase the operating expense ratio, including inadequate distribution cen-
ters, many medical institutions, and a high number of sales staff.
Pharmaceutical wholesalers in Europe, the US and Japan have been diversifying their 
pharmacy operations or manufacturing businesses because profits from wholesaling are low. 
This factor has contributed to regional differences in both wholesalers’ business models and 
their business development strategies. The result has been a process of market consolidation, 
regional expansion, and vertical integration.
3.2 Horizontal integration
The wholesalers integration process in the US is already complete, while in Europe and 
Japan it is not. In Europe, the increase in merger and acquisition activity has formed an oli-
gopolistic market. As a result, Celesio, Alliance Boots, and Phoenix account about a half of the 
European pharmaceutical wholesale market share. The competition among these three whole-
salers in the European market is severe. Although Alliance Boots has fought for first place in 
the UK and France, Celesio maintains its lead there, and ranks second in Germany. Phoenix is 
the leading pharmaceutical company in Germany, and ranks third in the UK. The European 
market is increasingly more competitive especially in the UK pre-wholesale market, where 
major UK pharmaceutical manufacturers distribute their products directly to pharmacies, and in 
developing countries such as those in Eastern Europe.
On the other hand, due to a reorganization in 2001, America’s top five wholesalers were 
consolidated into three larger companies. In 2008, they monopolized the market, holding 96% 
of the industry market share. McKesson, Cardinal Health, and AmerisourceBergen held 35%, 
33%, and 28% market share respectively. While these wholesalers continue to tolerate low 
profits, direct shipping to pharmacy chain distribution centers has increased.
Japan’s wholesalers are consolidated into four large companies : Medipal Holdings (HD) ; 
Alfresa HD ; Suzuken ; and Toho HD. Together, they hold 76% of the Japanese market. 
Each wholesaler’s products are sold nationwide. Each wholesaler’s survival depends on cut-
ting sales staff and expanding scale against a long-term downturn in profitability.
3.3 Regional expansion
Currently, pharmaceutical wholesaling is predominantly a national business, since a single 
market for pharmaceuticals is far from being achieved. Nonetheless, regional expansion into 
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promising growth markets is the strategic cornerstone in each corporation’s realignment pro-
cess. European wholesalers have focused on emerging economies, which present opportuni-
ties for strong, high-margin growth.
Celesio has entered the US, Australia and Brazil as well as East Europe. Phoenix has also 
entered the Scandinavian countries, the three Baltic States, Russia, and East Europe. Alliance 
Boots has stepped into Turkey, the Middle East, China, and areas of Africa, including Egypt and 
Algeria.
Each US wholesaler has expanded its business operations in Canada. Cardinal Health’s 
manufactured products are sold directly or through third-party distributors in the US, Canada, 
Europe, South America, and the Asia/Pacific Region. AmerisourceBergen has five business 
units and more than 13,000 associates in the US, Puerto Rico, Canada, and the United Kingdom.
The top four Japanese wholesalers each created a joint venture with Chinese pharmaceuti-
cal companies in order to break into the Chinese market. Service levels differ by region. 
This is due to regional economic disparities between Japan and China, and also due to the con-
siderable differences in the concept of a health care system and its historical process between 
these two countries. Attention will focus on whether the function of the Japanese wholesaler 
can be fulfilled in China.
3.4 Vertical integration
Although it is bound by regulations in different countries, integration between wholesalers 
and pharmacies is a key trend (Kanavos et al., 2011). The pharmacy operations that resulted 
from pharmaceutical wholesalers’ business diversifications are outlined as follows : Alliance 
Boots reported revenue of £7.7 billion (US$12 billion) in the health and beauty sector, and Cele-
sio reported revenue of €3.6 billion (US$4.8 billion) in the patient and consumer solutions divi-
sion. Their pharmacy business constitutes 33.5% and 15.7% respectively. Phoenix does not 
disclose the segment information on its pharmacy business, but it is estimated that the it 
accounts for a large percentage of its total sales.
The UK is one of the largest markets in the European retail pharmacy sector. According 
to the Office of Fair Trading (OFT) report, Alliance Boots holds the largest share of the UK 
retail pharmacy market at 18.3% (Office of Fair Trading, 2010). Lloyds Pharmacy, owned by 
Celesio, holds the second largest market share at 12.9%. Rowlands Pharmacy, owned by 
Phoenix, is the UK pharmacy sector’s fourth largest chain at 3.8% of market share. The phar-
macy chains owned by the top three European wholesalers are ranked strongly and maintain a 
solid presence in the UK retail pharmacy market.
Celesio, with its 2,281 retail pharmacies, is currently represented in seven coun-
tries. Alliance Boots runs more than 3,300 health and beauty retail stores in 11 countries, and 
the Phoenix group operates around 1,550 of its own pharmacies in 12 countries. In 1997, 
Celesio acquired Lloyds Chemists. In 2007, it also acquired DocMorris, Germany’s best-
known pharmacy brand and Europe’s largest mail-order pharmacy. Alliance Boots has 
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expanded its pharmacy business. In 2006, for example, former drugstores Boots Group and 
Alliance UniChem merged in order to more effectively compete with the supermarket chains. 
In Europe, however, the regulations on pharmacy operations differ by country. Each country-
specific barrier still remains. For example, in Germany, ownership of a pharmacy is restricted 
to registered pharmacists and only self-employed pharmacists are permitted to individually 
operate a maximum of four outlets.
In the US, large pharmacy chains have increased their share of the pharmacy market and, 
as a result, American pharmaceutical wholesalers have little market share. US wholesalers 
have integrated retailing through franchising. McKesson has developed Health Mart, which 
has one of the industry’s most comprehensive pharmacy franchise programs and consists of a 
network of 2,800 independently owned pharmacies with annual sales of US$6,920 million. 
Health Mart stores are distributed in proportion to the population, but have also developed in 
relatively low population areas where few chain stores are found, including Alabama and Michi-
gan (Figure 4). Cardinal Health also owns the Medicine Shoppe International (MSI) franchise 
chain. This company has 658 franchises and is the largest franchisor of independent commu-
nity pharmacies in the US with annual sales of US$1,320 million. Moreover, Cardinal Health 
serves the Leader program, which is a national network of independent pharmacies that com-
bines the resources and purchasing power necessary to generate chain-like benefits. The 
Leader network owns the name Leader Pharmacies, and has more than 3,300 independent 
community pharmacies throughout the US. AmerisourceBergen has a business affiliation with 
Good Neighbor Pharmacy, which is a retailer’s cooperative network of 4,300 independent phar-
macies with annual sales of US$11,300 million.
Because dispensing by doctors has continued in Japan, pharmacy chains have not yet 
achieved to their full potential growth. Nevertheless, Japan’s wholesalers have been expand-
Figure 4 Map of McKesson’s franchise chain (Health Mart), September 2010
  Source : Website of Health Mart, National Atlas of the US
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ing their pharmacy businesses in recent years. In fiscal 2011, Suzuken and Toho HD recorded 
annual sales of ¥76.7 billion (US$926 million) and ¥75.7 billion (US$914 million) respectively 
for their dispensing pharmacy business. PharmaCluster, a subsidiary of Toho HD, manages 
group pharmacies, which operated a total of 393 stores for the 2011 fiscal year. On the other 
hand, as of January 2013, Pfercos, one of Suzuken’s subsidiaries, operates 182 stores. Each 
wholesaler’s pharmacy business shows high operating profits of between 5% and 6%. These 
percentages are higher than those of wholesaling businesses alone and have contributed to the 
improvement of consolidated operating profits.
Wholesalers’ business divisions other than their wholesaling or pharmacy businesses 
include business solutions and pharmaceuticals manufacturing. In the 2011 fiscal year, Cele-
sio’s manufacturing solutions division generated gross profits of €383 million (US$511 million). 
The solutions division consists of business logistics solutions, marketing solutions, and the spe-
cialty pharmaceuticals business. The same fiscal year, the McKesson technology solutions 
division generated sales of US$3.3 billion. This division provides a comprehensive portfolio of 
software, automation, support and services to help healthcare organizations improve quality and 
patient safety, reduce the cost and variability of care and better manage their resources and rev-
enue stream. This division also includes clinical criteria solution, medical management tools, 
claims payment solutions, network performance tools, and care management programs. Since 
2009, Phoenix has been supporting its pharmacies by continually introducing a specific software 
solution for category management in the various countries in which it operates. In the 2012 
fiscal year, AmerisouceBergen’s business division, which generates revenues of US$1.3 billion, 
provided commercialization support services including reimbursement support programs, out-
comes research, contract field staffing, patient assistance and copay assistance programs, adher-
ence programs, risk mitigation services, and other market access programs to pharmaceutical 
and biotechnology manufacturers. This division also provides global specialty transportation 
and logistics to the biopharmaceutical industry.
As a manufacturing business, Alliance Boots manufactures consumer health and beauty 
products for internal supply and third party brands. It also produces special prescription medi-
cines for individual use. This division’s total revenue is £0.3 billion (US$411 million). Cardi-
nal Health’s medical division also manufactures, sources, and develops its own line of private 
brand medical and surgical products. This division’s total revenue is US$9.6 billion. In Japan, 
Suzuken sold ¥66.2 billion (US$799 million) and Alfresa HD sold ¥26.8 billion (US$323 million) 
in their manufacturing businesses.
For some companies, making a profit from some of these business activities has proven to 
be difficult, others have been forced to close up operations. Nevertheless, other aspects of 
this business have become a stable source of income and have generated a synergistic effect.
52 Tsutomu NAKAMURA
4. Factors of regional differences in the wholesale pharmaceutical industry
4.1 Regional differences in the function of pharmaceutical wholesalers
Japanese wholesalers perform the following five main functions : a) delivery and inventory 
management, b) bill collection and credit management, c) collection and the provision of infor-
mation, d) price determination, e) product promotion to prescribing physicians. Wholesalers 
in the US and Europe, on the other hand, perform only the first two functions. In terms of the 
delivery function, US wholesalers deliver pharmaceuticals in bulk, with large discounts, to 
drugstore chains’ distribution centers. This leads to a reduction in delivery frequency, the 
density of wholesalers’ distribution centers, but an increase in trade volume per order and an 
increase in the size of their distribution centers. As a result, each country’s market character-
istics affect delivery frequency, trade volume per order, and the size and density of wholesalers’ 
distribution centers. Because they cannot make a good profit from wholesaling, US and Euro-
pean wholesalers are presently diversifying into such areas as pharmacy operations or manufac-
turing. This diversification becomes a factor that contributes to regional differences in both 
the business model and business development of wholesalers. In this way, regional differences 
in pharmaceutical wholesaling result from wholesalers’ corporate strategies, which place value 
on each country’s specific market characteristics, especially the drug pricing system and the 
power relationships among healthcare providers in price determination.
4.2 Regional differences in pharmaceutical wholesalers’ risk
Wholesalers expected function differs from country to country. As a result, there are 
many differences in wholesalers’ relative risk (Figure 5). American and European wholesalers 
carry less risk in debt collection than do manufacturers or users (purchasers). As the US and 
European pharmaceutical supply chains are based on regular delivery and a short receivables 
turnover period, wholesalers have a low risk of failing to collect a receivable. Medical repre-
Figure 5 Differences in wholesalers’ relative risk
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sentatives (MRs) of manufacturers give drug information to customers. Reimbursement 
prices in the US are determined through negotiations between pharmaceutical manufacturers 
and private insurance companies, with wholesaler and pharmacy margins open to free competi-
tion based on service level. In the US, the UK, and Germany, prices of new drugs are freely 
determined by pharmaceutical manufacturers. Many European countries rely on a system 
wherein wholesaler and pharmacy margins are controlled on an official basis. Support to man-
ufacturers’ MRs is not a major part of wholesalers’ operations. As a result, American and 
European wholesalers play only a limited role in the wholesaling business and, consequently, in 
order to increase their profitability, they do not have much choice but to expand regionally or to 
integrate vertically. These business environments have become incentives for the pursuit of 
efficiency and added value.
In Japan, by contrast, risk is higher among pharmaceutical wholesalers compared to manu-
facturers and medical institutions or pharmacies. The functions of Japanese wholesalers 
include irregular deliveries in emergencies, a long receivables turnover period, complex inven-
tory management, the provision of information, the performance of necessary recalls, price 
negotiations, and product promotion to prescribing physicians. In the US and Europe, many of 
these functions are the responsibility of each manufacturer and retailer. Before the change in 
regulation, pharmaceutical manufacturers had taken most of the risk. The manufacturers 
believed in wholesalers’ high performance in price negotiation, product promotion, and the pro-
vision of information. While the wholesalers had acted as selling agents for the manufacturers, 
the manufacturers ensured profits to wholesalers by covering deficits. This means that the 
manufacturers had taken the risk on behalf of the wholesalers and wielded de facto control over 
the prices actually paid to them by users. Nevertheless, continuing biennial NHI price cuts 
and an invoice price system in effect since 1992 that squeezed the distribution margin forced 
manufacturers to shift the risk onto wholesalers. And despite the increased relative risk that 
the wholesalers take, risk taking is not reflected in their profits.
While health care systems or power relationships among health-care providers are signifi-
cantly different by country, one thing the existing wholesaling businesses all have in common is 
a decline in profits. The relative high risk interferes with further efficiency, especially in the 
Japanese pharmaceutical wholesaling industry. It requires an inefficient supply chain based on 
decentralized locations of wholesalers’ distribution centers.
5. Conclusions
Japanese, the US, and European pharmaceutical wholesalers have been expanding their 
businesses to developing countries such as China with little prospect for expanding to devel-
oped countries. The market environment, including that of the health care system, varies 
greatly between the existing major markets and new markets. As a result, it can be said that 
there are many ways to serve local market needs. The questions that must be addressed, in 
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this case, are : How does global inter-firm competition and restructuring service the local 
demand for pharmaceuticals? How does it affect the power relationships among stakeholders 
in the supply chain? And how did changes in the pharmaceutical supply chain affect access to 
pharmaceuticals? 
In order to achieve fiscal soundness and affordable health care insurance systems in devel-
oped countries, further reductions in pharmaceutical supply costs will be required. Pharma-
ceutical wholesalers will need to make more efforts to maintain a stable and efficient pharma-
ceutical supply system. At the same time, in order to survive, pharmaceutical wholesalers will 
need to act as health care service providers and also provide business solutions in addition to 
their wholesaling function. Pharmaceutical wholesaling is also expected to restructure geo-
graphically, reflecting various local needs. The interregional comparative analysis adopted in 
this article is an effective way to illustrate the global wholesale space that could result from 
increased inter-firm competition. This is a subject that should be pursued in order to clarify 
the mechanism of global restructuring of the pharmaceutical supply chain.
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